Hormonal
Prescription omega-3 fatty acids (EPA+DHA or EPA-only) at a dose of 4 g/d reduce triglycerides by 30-35% in patients with very high triglycerides (≥500 mg/dL) and by approximately 27% in those with high triglycerides (200-499 mg/dL).
If you have high triglycerides, ask your doctor about prescription omega-3s (like Vascepa or Lovaza) taken at 4 grams per day. These are different from store-bought supplements because they are held to stricter FDA standards. They can lower your triglycerides by about 30%, but you should also focus on lifestyle changes like losing weight, limiting alcohol, and managing blood sugar.
In treatment of very high triglycerides with 4 g/d, EPA+DHA agents reduce triglycerides by ≥30%... On average, the triglyceride reduction was ≈27% (range, 21%–35%) [in HTG].
Why this rating
Based on multiple randomized controlled trials and FDA-approved agents, though direct head-to-head comparisons are lacking.
Source
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
Ann C. Skulas‐Ray et al. · Circulation · 2019
DOI 10.1161/cir.0000000000000709
More from this paper
- Prescription omega-3s (4 g/d EPA-only) reduce major adverse cardiovascular events by 25% in high-risk patients with hypertriglyceridemia who are already taking statins.Strong
- EPA-only prescription omega-3s (Icosapent Ethyl) do not raise LDL cholesterol in patients with very high triglycerides, whereas EPA+DHA combinations may increase LDL-C by 15-36%.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →